Prophylactic Ranibizumab Injections Fail to Halt AMD Progression

A recent study published in the Translational Vision Science & Technology revealed that prophylactic ranibizumab (PR) injections administered every three months have shown no substantial impact on intermediate nonexudative age-related macular degeneration (AMD).

The PREVENT trial aimed at evaluating the efficacy of PR injections, focused on assessing their influence on drusen volume, macular layer thicknesses, and the progression of geographic atrophy (GA) area over a 24-month period.

The study compared two groups of individuals with intermediate AMD: one group receiving PR injections and another receiving sham injections as a control. Researchers analyzed various parameters using spectral-domain optical coherence tomography and fundus autofluorescence images to determine any notable differences between the two groups.

The results of the analysis showed no statistically significant differences between the PR group and the control group in terms of drusen area and volume. Furthermore, both groups exhibited similar reductions in central subfield thickness, mean cube thickness, cube volume, and retinal sublayer thickness over the 24-month period. These findings underscored the ineffectiveness of PR injections in altering the anatomical characteristics of the macula in intermediate AMD patients.